Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: | Recruiting |
---|---|
Conditions: | Cancer, Brain Cancer, Brain Cancer, Brain Cancer, Brain Cancer, Infectious Disease, Lymphoma, Lymphoma, Hematology |
Therapuetic Areas: | Hematology, Immunology / Infectious Diseases, Oncology |
Healthy: | No |
Age Range: | Any - 21 |
Updated: | 4/6/2019 |
Start Date: | October 1, 2018 |
End Date: | December 31, 2025 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients
with solid tumors that have spread to other places in the body (advanced), non-Hodgkin
lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling
pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that
control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many
types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the
MAPK pathway.
with solid tumors that have spread to other places in the body (advanced), non-Hodgkin
lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling
pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that
control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many
types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the
MAPK pathway.
PRIMARY OBJECTIVES:
I. To determine the objective response rate (ORR; complete response + partial response) in
pediatric patients treated with BVD-523FB (ulixertinib) with advanced solid tumors (including
central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that
harbor activating genetic alterations in the MAPK pathway.
SECONDARY OBJECTIVES:
I. To estimate the progression free survival in pediatric patients treated with BVD-523FB
(ulixertinib) with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or
histiocytic disorders that harbor activating genetic alterations in the MAPK pathway.
II. To obtain information about the tolerability of BVD-523FB (ulixertinib) in children and
adolescents with relapsed or refractory cancer.
III. To provide preliminary estimates of the pharmacokinetics of BVD-523FB (ulixertinib) in
children and adolescents with relapsed or refractory cancer.
EXPLORATORY OBJECTIVES:
I. To evaluate other biomarkers as predictors of response to BVD-523FB (ulixertinib) and
specifically, whether tumors that harbor different mutations or fusions will demonstrate
differential response to BVD-523FB (ulixertinib) treatment.
II. To explore approaches to profiling changes in tumor genomics over time through evaluation
of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE: This is a dose-escalation study.
Patients receive ulixertinib orally (PO) twice daily (BID). Courses repeat every 28 days for
up to 2 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
I. To determine the objective response rate (ORR; complete response + partial response) in
pediatric patients treated with BVD-523FB (ulixertinib) with advanced solid tumors (including
central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that
harbor activating genetic alterations in the MAPK pathway.
SECONDARY OBJECTIVES:
I. To estimate the progression free survival in pediatric patients treated with BVD-523FB
(ulixertinib) with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or
histiocytic disorders that harbor activating genetic alterations in the MAPK pathway.
II. To obtain information about the tolerability of BVD-523FB (ulixertinib) in children and
adolescents with relapsed or refractory cancer.
III. To provide preliminary estimates of the pharmacokinetics of BVD-523FB (ulixertinib) in
children and adolescents with relapsed or refractory cancer.
EXPLORATORY OBJECTIVES:
I. To evaluate other biomarkers as predictors of response to BVD-523FB (ulixertinib) and
specifically, whether tumors that harbor different mutations or fusions will demonstrate
differential response to BVD-523FB (ulixertinib) treatment.
II. To explore approaches to profiling changes in tumor genomics over time through evaluation
of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE: This is a dose-escalation study.
Patients receive ulixertinib orally (PO) twice daily (BID). Courses repeat every 28 days for
up to 2 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Inclusion Criteria:
- Patient must have enrolled onto APEC1621SC and must have been given a treatment
assignment to MATCH to APEC1621J based on the presence of an actionable mutation.
- Patients must have a body surface area >= 0.54 m^2 at the time of study enrollment.
- Patients must have radiographically measurable disease at the time of study
enrollment. Patients with neuroblastoma who do not have measurable disease but have
metaiodobenzylguanidine (MIBG)+ evaluable disease are eligible. Measurable disease in
patients with central nervous system (CNS) involvement is defined as tumor that is
measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and
visible on more than one slice.
- Note: The following do not qualify as measurable disease:
- Malignant fluid collections (e.g., ascites, pleural effusions)
- Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
- Lesions only detected by nuclear medicine studies (e.g., bone, gallium or
positron emission tomography [PET] scans) except as noted for neuroblastoma
- Elevated tumor markers in plasma or cerebrospinal fluid (CSF)
- Previously radiated lesions that have not demonstrated clear progression
post radiation
- Leptomeningeal lesions that do not meet the measurement requirements for
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16
years of age. Note: Neurologic deficits in patients with CNS tumors must have been
relatively stable for at least 7 days prior to study enrollment. Patients who are
unable to walk because of paralysis, but who are up in a wheelchair, will be
considered ambulatory for the purpose of assessing the performance score.
- Patients must have fully recovered from the acute toxic effects of all prior
anti-cancer therapy and must meet the following minimum duration from prior
anti-cancer directed therapy prior to enrollment. If after the required timeframe, the
numerical eligibility criteria are met, e.g. blood count criteria, the patient is
considered to have recovered adequately.
- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive.
- >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy
(42 days if prior nitrosourea).
- Anti-cancer agents not known to be myelosuppressive (e.g. not associated with
reduced platelet or ANC counts): >= 7 days after the last dose of agent.
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody,
and toxicity related to prior antibody therapy must be recovered to Grade =< 1.
- Corticosteroids: If used to modify immune adverse events related to prior
therapy, ≥ 14 days must have elapsed since last dose of corticosteroid.
- Hematopoietic growth factors: >= 14 days after the last dose of a long-acting
growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For
growth factors that have known adverse events occurring beyond 7 days after
administration, this period must be extended beyond the time during which adverse
events are known to occur. The duration of this interval must be discussed with
the study chair and the study-assigned Research Coordinator.
- Interleukins, Interferons and Cytokines (other than hematopoietic growth
factors): >= 21 days after the completion of interleukins, interferon or
cytokines (other than hematopoietic growth factors).
- Stem cell Infusions (with or without TBI):
- Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem
cell infusion including DLI or boost infusion: >= 84 days after infusion and
no evidence of GVHD.
- Autologous stem cell infusion including boost infusion: >= 42 days.
- Cellular Therapy: >= 42 days after the completion of any type of cellular therapy
(e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.).
- Radiotherapy (XRT)/External Beam Irradiation including Protons: >= 14 days after
local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of
the pelvis; >= 42 days if other substantial brain metastases (BM) radiation.
- Note: Radiation may not be delivered to "measurable disease" tumor site(s)
being used to follow response to subprotocol treatment.
- Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days
after systemically administered radiopharmaceutical therapy.
- Patients must not have received prior exposure to BVD-523FB (ulixertinib) or
other ERK inhibitors.
- For patients with solid tumors without known bone marrow involvement: Peripheral
absolute neutrophil count (ANC) >= 1000/mm^3 (within 7 days prior to enrollment).
- For patients with solid tumors without known bone marrow involvement: Platelet count
>= 100,000/mm^3 (transfusion independent, defined as not receiving platelet
transfusions for at least 7 days prior to enrollment).
- Patients with known bone marrow metastatic disease will be eligible for study (may
receive transfusions provided they are not known to be refractory to red cell or
platelet transfusions). These patients will not be evaluable for hematologic toxicity.
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70ml/min/1.73
m^2, or (within 7 days prior to enrollment).
- A serum creatinine based on age/gender (within 7 days prior to enrollment).
- Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for
age (within 7 days prior to enrollment).
- Serum glutamate-pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135
U/L. (For the purpose of this study, the ULN for SGPT is 45 U/L.) (within 7 days prior
to enrollment).
- Serum albumin >= 2 g/dL (within 7 days prior to enrollment).
- Shortening fraction of >= 27% by echocardiogram, or (within 7 days prior to
enrollment).
- Ejection fraction of >= 50% by gated radionuclide study (within 7 days prior to
enrollment).
- QTc interval =< 480 milliseconds (within 7 days prior to enrollment).
- Patients must be able to swallow intact capsules.
- All patients and/or their parents or legally authorized representatives must sign a
written informed consent. Assent, when appropriate, will be obtained according to
institutional guidelines.
Exclusion Criteria:
- Pregnant or breast-feeding women will not be entered on this study due to risks of
fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests
must be obtained in girls who are post-menarchal. Males or females of reproductive
potential may not participate unless they have agreed to use an effective
contraceptive method for the duration of study treatment and for 3 months after last
dose of BVD-523FB (ulixertinib).
- Patients receiving corticosteroids who have not been on a stable or decreasing dose of
corticosteroid for at least 7 days prior to enrollment are not eligible. If used to
modify immune adverse events related to prior therapy, >= 14 days must have elapsed
since last dose of corticosteroid.
- Patients who are currently receiving another investigational drug are not eligible.
- Patients who are currently receiving other anti-cancer agents are not eligible.
- Patients who are receiving cyclosporine, tacrolimus or other agents to prevent
graft-versus-host disease post bone marrow transplant are not eligible for this trial.
- Patients who are currently receiving drugs that are strong inducers or inhibitors of
CYP3A4 are not eligible. Strong inducers or inhibitors of CYP3A4 should be avoided
from 14 days prior to enrollment to the end of the study. Note: CYP3A4 inducing
anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose,
are allowed.
- Patients who are currently receiving drugs that are strong inducers or inhibitors of
CYP1A2 and CYP2D6 are not eligible. Strong inhibitors of CYP1A2 (eg., ciprofloxacin,
enoxacin, fluvoxamine, zafirlukast) should be avoided from 14 days prior to enrollment
to the end of the study. Strong inhibitors of CYP2D6 (e.g., bupropion, paroxetine,
fluoxetine, quinidine, terbinafine) should also be avoided from 14 days prior to
enrollment to the end of the study.
- Patients with known significant ophthalmologic conditions (uncontrolled glaucoma,
history of retinal vein occlusion or retinal detachment, excluding patients with
longstanding findings secondary to existing conditions) are not eligible.
- Patients who have an uncontrolled infection are not eligible.
- Patients who have received a prior solid organ transplantation are not eligible.
- Patients who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study are not eligible.
We found this trial at
73
sites
Charlotte, North Carolina 28204
Principal Investigator: Joel A. Kaplan
Phone: 800-804-9376
Click here to add this to my saved trials
4900 Mueller Boulevard
Austin, Texas 78723
Austin, Texas 78723
(512) 324-0000
Principal Investigator: Amy C. Fowler
Dell Children's Medical Center of Central Texas Welcome to Dell Children
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Elizabeth D. Alva
Children's Hospital of Alabama Children
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Clare J. Twist
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Jessica L. Heath
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
Cincinnati, Ohio 45229
1-513-636-4200
Principal Investigator: Erin H. Breese
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
Click here to add this to my saved trials
7777 Forest Ln # C840
Dallas, Texas 75230
Dallas, Texas 75230
(972) 566-7000
Principal Investigator: Stanton C. Goldman
Phone: 972-566-5588
Medical City Dallas Hospital If you have concerns for your health, that of a family...
Click here to add this to my saved trials
1200 Pleasant Street
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-KIDS
Principal Investigator: Samantha L. Mallory
Blank Children's Hospital Blank Children's Hospital is completely dedicated to meeting the unique health care...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Anderson (Andy) B. Collier
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
Los Angeles, California 90027
(323) 660-2450
Principal Investigator: Fariba Navid
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Alberto S. Pappo
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
601 Children's Lane
Norfolk, Virginia 23507
Norfolk, Virginia 23507
(757) 668-7000
Principal Investigator: Eric J. Lowe
Children's Hospital of The King's Daughters Children
Click here to add this to my saved trials
747 52nd St
Oakland, California 94609
Oakland, California 94609
(510) 428-3000
Principal Investigator: Carla B. Golden
Children's Hospital and Research Center Oakland For nearly 100 years, Children's Hospital & Research Center...
Click here to add this to my saved trials
530 Northeast Glen Oak Avenue
Peoria, Illinois 61603
Peoria, Illinois 61603
(309) 624-4945
Principal Investigator: Jaime M. Libes
Phone: 888-226-4343
Saint Jude Midwest Affiliate The Jim and Trudy Maloof St. Jude Midwest Affiliate Clinic was...
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
215-590-1000
Principal Investigator: Elizabeth Fox
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Jean M. Tersak
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Linda C. Stork
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Gita V. Massey
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Angela R. Girvin
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Anne-Marie R. Langevin
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Rajen Mody
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Douglas J. Scothorn
Phone: 828-213-4150
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Margaret E. Macy
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Kenneth J. Cohen
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Nadine P. SantaCruz
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Katherine A. Janeway
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Katherine A. Janeway
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Theodore W. Laetsch
Phone: 214-648-7097
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Jagadeesh Ramdas
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
Click here to add this to my saved trials
9333 Imperial Highway
Downey, California 90242
Downey, California 90242
Principal Investigator: Robert M. Cooper
Phone: 510-891-3400
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Susan G. Kreissman
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
Fort Worth, Texas 76104
(682) 885-4000
Principal Investigator: Kelly L. Vallance
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Katharine Offer
Phone: 201-996-2879
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Jodi Muscal
Phone: 713-798-1354
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
(317) 944-5000
Principal Investigator: Kamnesh R. Pradhan
Phone: 800-248-1199
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Mariko Sato
Phone: 800-237-1225
Click here to add this to my saved trials
Kansas City, Missouri 64108
Principal Investigator: Kevin F. Ginn
Click here to add this to my saved trials
2018 W Clinch Ave
Knoxville, Tennessee 37916
Knoxville, Tennessee 37916
(865) 541-8000
Principal Investigator: Ray C. Pais
Phone: 865-541-8266
East Tennessee Children's Hospital East Tennessee Children's Hospital is a not-for-profit, private, independent pediatric medical...
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: David L. Becton
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
Click here to add this to my saved trials
11234 Anderson St
Loma Linda, California 92354
Loma Linda, California 92354
(909) 558-4000
Principal Investigator: Albert Kheradpour
Phone: 909-558-3375
Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...
Click here to add this to my saved trials
Long Beach, California 90806
Principal Investigator: Pamela H. Kempert
Click here to add this to my saved trials
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Kenneth B. De Santes
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Julio C. Barredo
Phone: 305-243-2647
Click here to add this to my saved trials
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Emily G. Greengard
Click here to add this to my saved trials
2525 Chicago Ave
Minneapolis, Minnesota 55404
Minneapolis, Minnesota 55404
(612) 813-6000
Principal Investigator: Michael K. Richards
Children's Hospitals and Clinics of Minnesota - Minneapolis Children's Hospitals and Clinics of Minnesota is...
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Scott C. Borinstein
Phone: 800-811-8480
Click here to add this to my saved trials
New Hyde Park, New York 11040
Principal Investigator: Julie I. Krystal
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Craig Lotterman
Phone: 504-703-8712
Click here to add this to my saved trials
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Alice Lee
Phone: 212-305-6361
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Sharon L. Gardner
Phone: 212-263-4434
Click here to add this to my saved trials
Oakland, California 94611
Principal Investigator: Laura A. Campbell
Phone: 877-642-4691
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: Rene Y. McNall-Knapp
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
Click here to add this to my saved trials
8200 Dodge St
Omaha, Nebraska 68114
Omaha, Nebraska 68114
(402) 955-5400
Principal Investigator: Minnie Abromowitch
Children's Hospital and Medical Center of Omaha Children's Hospital & Medical Center has a rich...
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
Omaha, Nebraska 68198
(402) 559-4000
Principal Investigator: Minnie Abromowitch
Phone: 402-559-6941
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Don E. Eslin
Phone: 321-843-2584
Click here to add this to my saved trials
2801 N Gantenbein Ave
Portland, Oregon 97227
Portland, Oregon 97227
(503) 276-6500
Principal Investigator: Janice F. Olson
Legacy Emanuel Children's Hospital For generations our children's hospital has provided outstanding care for kids...
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Carola A. Arndt
Phone: 855-776-0015
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Robert J. Hayashi
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
San Antonio, Texas 78207
Principal Investigator: Timothy C. Griffin
Click here to add this to my saved trials
San Francisco, California 94158
Principal Investigator: Robert E. Goldsby
Phone: 877-827-3222
Click here to add this to my saved trials
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Douglas S. Hawkins
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
Click here to add this to my saved trials
101 W 8th Ave
Spokane, Washington 99204
Spokane, Washington 99204
(509) 474-3131
Principal Investigator: Judy L. Felgenhauer
Providence Sacred Heart Medical Center & Children's Hospital When Mother Joseph and the Sisters of...
Click here to add this to my saved trials
Syracuse, New York 13214
Principal Investigator: Philip M. Monteleone
Phone: 315-464-5476
Click here to add this to my saved trials
9040 Jackson Ave
Tacoma, Washington 98431
Tacoma, Washington 98431
(253) 968-1110
Principal Investigator: Melissa A. Forouhar
Phone: 253-968-0129
Madigan Army Medical Center Located on Joint Base Lewis-McChord, Madigan Army Medical Center comprises a...
Click here to add this to my saved trials
Tampa, Florida 33607
Principal Investigator: Dana A. Obzut
Click here to add this to my saved trials
2142 N Cove Blvd
Toledo, Ohio 43606
Toledo, Ohio 43606
(419) 291-5437
Principal Investigator: Jamie L. Dargart
Phone: 419-824-1842
The Toledo Hospital/Toledo Children's Hospital ProMedica's Mission is to improve your health and well-being. And...
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Jeffrey S. Dome
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
Click here to add this to my saved trials